BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48 ...

We recently published a list of Top 10 AI Stocks Making Headlines Today In this article, we are going to take a look at where ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

As previously reported, BTIG initiated coverage of Tempus AI (TEM) with a Buy rating and $60 price target Tempus AI is a rapidly growing ...

Fintel reports that on April 21, 2025, BTIG initiated coverage of Tempus AI (NasdaqGS:TEM) with a Buy recommendation. Analyst ...

With markets showing signs of life again, some of the most oversold stocks are going along for the ride. That includes ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

"In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...